A New Over-the-Counter Naloxone Nasal Spray Is Now Available at Pharmacies
The FDA approved Rextovy, a 4 mg naloxone hydrochloride nasal spray by Amphastar Pharmaceuticals, for over-the-counter sale on June 16, 2026. It joins Narcan (Emergent BioSolutions) and RiVive (Harm Reduction Therapeutics) as OTC naloxone options. The article cites overdose-death figures and says expanded access may affect retail pricing and availability.
How this was made
The 30-second read
Why it matters
For traders, the key new fact is the FDA approval and immediate OTC availability of a specific competitor product, which can shift expectations for naloxone market growth and competitive pricing.
Market read
A primary regulatory approval for an OTC naloxone product can affect near-term demand expectations and competitive pricing dynamics in the US overdose-reversal market.
What to watch
The article does not provide pricing, launch timing by chain, or expected unit sales; competitive pricing pressure could offset volume gains.
Background
FDA approved a third OTC naloxone nasal spray, Rextovy (4 mg naloxone hydrochloride), manufactured by Amphastar Pharmaceuticals, expanding public access without a prescription.
Ticker impact
FDA approved Rextovy, a 4 mg naloxone nasal spray manufactured by Amphastar Pharmaceuticals, now sold OTC at pharmacies and online.
Near-term sentiment tailwind possible from expanded distribution, but magnitude uncertain without sales/market-share data.
The article is a primary FDA approval and product availability update for Amphastar’s specific product (Rextovy), which can change near-term demand expectations versus prescription-only access.
Market effects
Adds a third OTC naloxone competitor, which may pressure retail pricing and increase competitive intensity in overdose-reversal products.
US-focused distribution expansion at pharmacies, convenience stores, and online.
Limited direct global relevance, but reinforces a broader trend toward OTC access for emergency antidotes.
Counterpoint
OTC naloxone demand may be constrained by awareness, stocking practices, and reimbursement dynamics, so incremental volume may be slower than expected.
Key entities
- ProductRextovy
4 mg naloxone hydrochloride nasal spray approved OTC by FDA on June 16, 2026.
- CompanyAmphastar Pharmaceuticals
Manufacturer of Rextovy; subject of the approval and availability update.
- RegulatorFDA
Approved the third OTC naloxone nasal spray, broadening access.
- ProductNarcan
OTC naloxone nasal spray by Emergent BioSolutions, referenced as an existing competitor.
- ProductRiVive
OTC naloxone nasal spray by Harm Reduction Therapeutics, referenced as an existing competitor.
